Publication

Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.

Authors not recorded

JAMA Dermatol2014PMID 25317746stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

cancerMalignant Neoplasmcivic_curation1.00
cancerMelanomacivic_curation1.00
drugDasatinibcivic_curation1.00
drugImatinibcivic_curation1.00
geneKITcivic_curation1.00
variantKIT D816Vcivic_curation1.00
variantKIT L576Pcivic_curation1.00
variantKIT S628Ncivic_curation1.00

Curated evidence

Evidence citing this paper (5)

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KIT D816V1
Dasatinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	accepted	EID7465 In in vitro studies, COS-7 cells transfected with KIT D816V mutant and TF-1 cells expressing KIT D816V were treated with imatinib (1 and 10 µM), and phosphorylation of the receptor was evaluated by we… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
KIT L576P1
Dasatinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4141 In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT aut… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
KIT S628N3
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	4	submitted	EID7462 WT and S628N KIT were expressed in COS-7 cells. Both cell types were treated with or without Stem Cell Factor (SCF), which induces KIT autophosphorylation (activation). In western blots, WT KIT was ph… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
Dasatinib + ImatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4791 In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-s… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic
Imatinib	Melanoma	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7463 A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S62… (full text at CIViC) PMID 25317746 · Vita et al., 2014 · Open in CIViC	civic